Abstract:BackgroundThe incidence of cefepime-induced neurotoxicity (CIN) has been previously underestimated, and there have only been sporadic reports from critical neurological settings. The present study aimed to investigate the potential factors associated with disease development, electroencephalography (EEG) sub-classification, and outcome measures.MethodsThe 10-year medical records of patients who underwent EEG between 2007 and 2016 at a tertiary medical center in Taiwan, and developed encephalopathy after cefepime therapy were retrospectively reviewed. Age- and sex-matched controls were included for further analysis. Demographic data, the occurrence of clinical seizures, non-convulsive status epilepticus (NCSE), use of antiepileptic drugs (AEDs), receiving maintenance or urgent hemodialysis, EEG findings, and functional outcomes were analyzed. The Chi-square test and a logistic regression model were applied to survey significant prognostic factors relating to mortality.ResultsA total of 42 CIN patients were identified, including 25 patients from wards and 17 from intensive care units; their mean age was 75.8 ± 11.8 years. Twenty-one patients (50%) had chronic kidney disease, and 18 (43%) had acute kidney injury. Among these patients, 32 (76%) received appropriate cefepime dose adjustment. Three patients had a normal renal function at the time of CIN onset. The logistic regression model suggested that maintenance hemodialysis and longer duration of cefepime use were independently associated with the development of CIN, with odds ratios of 3.8 and 1.2, respectively. NCSE was frequently noted in the CIN patients (64%). Generalized periodic discharge with or without triphasic morphology was the most common EEG pattern (38%), followed by generalized rhythmic delta activity and generalized spike-and-waves. AEDs were administered to 86% of the patients. A total of 17 patients (40%) did not survive to hospital discharge. Adequate cefepime dose adjustment and early cefepime discontinuation led to a better prognosis.ConclusionsCIN was associated with high mortality and morbidity rates. Neurotoxic symptoms could still occur when the cefepime dose was adjusted, or in patients with normal renal function. Patients with maintenance hemodialysis or a longer duration of cefepime therapy tended to develop CIN. Early recognition of abnormal EEG findings allowed for the withdrawal of the offending agent, resulting in clinical improvements and a better prognosis at discharge.

Cefepime-induced Neurotoxicity:Literature Analysis of 46 Cases

Cefepime-Induced Neurotoxicity in a 74-Year-Old Woman

Clinical, Electroencephalographic Features and Prognostic Factors of Cefepime-Induced Neurotoxicity: A Retrospective Study

The adverse reaction of cefepime neurotoxicity

Ceftazidime-related neurotoxicity in a patient with renal impairment: a case report and literature review

Danger in plain sight: determining who is at highest risk for cefepime induced neurotoxicity and its associated morbidity and mortality

Cefepime Induced Neurotoxicity in Patients With or Without a History of Seizures: A Retrospective Matched Cohort Study

The Prevalence and Drug Resistance of Strains Isolated from Cerebrospinal Fluid of Neurosurgery Patients During Period of 2011-2015

Acute kidney injury is associated with abnormal cefepime exposure among critically ill children and young adults

Analysis of factors related to cefepime adverse reaction

Clinical Pharmacokinetics and Pharmacodynamics of Cefepime

Ceftriaxone-Induced Encephalopathy in a Patient With Chronic Kidney Disease

Characterizing Ertapenem Neurotoxicity: A Systematic Review and Experience at a Tertiary Medical Center

Clinical Application and Evaluation of Cefepime

A Case-Report of Drug-Induced Mixed Liver Injury Resulting From Cefepime Exposure

Carbapenem Antibacterial Drugs Induced Adverse Drug Reaction

Analysis of 197 Cases of Adverse Drug Reactions in the Nervous System

The Neurotoxicity of Antibacterial Agents

Imipenem-Cilastatin-Induced Seizures: A Case Report

Successful Treatment of Ventriculitis Caused by MDR/XDR Gram-Negative Bacillus Using Ceftazidime/Avibactam: Case Series and Literature Review

Cefepime Clinical Pharmacokinetics